Onset of action of a topical antihistamine as assessed by histamine challenge-induced plasma exudation responses

Annals of Allergy, Asthma and Immunology

Volumn 96, Issue 2, 2006, Pages 345-348

  Korsgren, Magnus ^a   Andersson, Morgan ^a   Larsson, Lars ^b   Aldén Raboisson, Marie ^b   Greiff, Lennart ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Biolipox AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTIHISTAMINIC AGENT; AZELASTINE; CETIRIZINE; HISTAMINE; LEVOCABASTINE; PLACEBO;

ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVATION; DRUG MECHANISM; EXTRAVASATION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; NOSE MUCUS; PLASMA; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 33244496002     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61246-X     Document Type: Article

References (17)

1. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97:617-626.
2. Palma-Carlos AG, Palma-Carlos ML, Rombaut N. The effect of levocabastine nasal spray in nasal provocation test. Int J Clin Pharmacol Res. 1988;8:25-30.
3. Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79:163-172.
4. Corren J, Rachelefsky G, Spector S, et al. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. J Allergy Clin Immunol. 1999;103:574-580.
5. Day JH, Briscoe M, Rafeiro E, et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol. 2001;87:474-481.
6. Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the environmental exposure unit (EEU). Int J Clin Pract. 2004;58:109-118.
7. Svensson C, Baumgarten CR, Pipkorn U, et al. Reversibility and reproducibility of histamine induced plasma leakage in nasal airways. Thorax. 1989;44:13-18.
8. 2-macroglobulin into human nasal airways. Clin Exp Allergy. 1997;27:438-444.
9. Greiff L, Pipkorn U, Alkner U, Persson CGA. The "Nasal Pool-device" applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions. Clin Exp Allergy. 1990;20:253-259.
10. 2-macroglobulin and tryptase in allergic rhinitis. J Allergy Clin Immunol. 1995;96:97-103.
11. Svensjö E, Joyner WL. The effects of intermittent and continuous stimulation of microvessels in the cheek pouch of hamsters with histamine and bradykinin on the development of leaky sites. Microvasc Endothel Lymph. 1984;1:381-396.
12. Majno G, Palade GE, Schoefl GI. Studies on inflammation, II: the site of action of histamine and serotonin along the vascular tree: a topographic study. J Biophys Biochem Cytol. 1961;11:607-626.
13. Greiff L, Andersson M, Erjefält JS, Persson CG, Wollmer P. Airway microvascular extravasation and luminal entry of plasma. Clin Physiol Funct Imaging. 2003;23:301-306.
14. Grega GJ, Persson CGA, Svensjö E. Endothelial cell reactions to inflammatory mediators assessed by fluid and solute flux analysis. In: Ryan US, ed. Endothelial Cells. Boca Raton, FL: CRC Press; 1988:103-119.
15. Clement P, Roovers MHW, Francillon C, Dodion P. Dose-ranging, placebo-controlled study of cetirizine nasal spray in adults with perennial allergic rhinitis. Allergy. 1994;49:668-672.
16. Grant JA, Riethuisen J-M, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levo-cetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002;88:190-197.
17. Kaliner MA, White MV, Economides A, et al. Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Ann Allergy Asthma Immunol. 2003;90:629-634.